2-[2-[2-[(E)-3-azidoprop-1-enyl]phenoxy]ethoxy]oxane | 811867-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[2-[2-[(E)-3-azidoprop-1-enyl]phenoxy]ethoxy]oxane
• CAS: 811867-14-8
• 化学式: C₁₆H₂₁N₃O₃
• 分子量: 303.361
• InChiKey: MKYIZMZHJSJKRI-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[2-[2-[(E)-3-azidoprop-1-enyl]phenoxy]ethoxy]oxane 在 palladium on activated charcoal 氢气 、 N,N-二异丙基乙胺 、 三苯基膦 、 四甲基胍 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 (6R,9R,12S)-6-[(4-hydroxyphenyl)methyl]-9-propan-2-yl-12-propyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
  参考文献：
  名称：

  Discovery of a New Class of Macrocyclic Antagonists to the Human Motilin Receptor

  摘要：

  A novel class of macrocyclic peptidomimetics was identified and optimized as potent antagonists to the human motilin receptor (hMOT-R). Well-defined structure-activity relationships allowed for rapid optimization of potency that eventually led to high affinity antagonists to hMOT-R. Potency and antagonist functional activity were confirmed both in functional and cell-based assays, as well as on isolated rabbit intestinal smooth muscle strips. Rapid access to this novel class of macrocyclic target structures was made possible through two efficient and complementary solid-phase parallel synthetic approaches, both of which are reported herein.

  DOI：

  10.1021/jm0606600
• 作为产物：
  描述：

  反式-2-羟基肉桂酸 在 2,3,5-三甲基吡啶 、 三甲基氯硅烷 、 二异丁基氢化铝 、 甲基磺酰氯 、 lithium chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.5h， 生成 2-[2-[2-[(E)-3-azidoprop-1-enyl]phenoxy]ethoxy]oxane
  参考文献：
  名称：

  Discovery of a New Class of Macrocyclic Antagonists to the Human Motilin Receptor

  摘要：

  A novel class of macrocyclic peptidomimetics was identified and optimized as potent antagonists to the human motilin receptor (hMOT-R). Well-defined structure-activity relationships allowed for rapid optimization of potency that eventually led to high affinity antagonists to hMOT-R. Potency and antagonist functional activity were confirmed both in functional and cell-based assays, as well as on isolated rabbit intestinal smooth muscle strips. Rapid access to this novel class of macrocyclic target structures was made possible through two efficient and complementary solid-phase parallel synthetic approaches, both of which are reported herein.

  DOI：

  10.1021/jm0606600

文献信息

• Intermediates for macrocyclic compounds
  申请人：Marsault Eric

  公开号：US09181298B2

  公开（公告）日：2015-11-10

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及一种新型的大环化合物，其化学式为（I），以及其药用可接受的盐、水合物或溶剂化合物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所描述。该发明还涉及化合物的化学式（I），这些化合物是胃动素受体拮抗剂，可用于治疗与该受体相关的疾病以及与胃肠动力功能障碍相关的疾病。
• INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20090240027A1

  公开（公告）日：2009-09-24

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，其为胃动素受体拮抗剂，并可用于治疗与该受体及运动功能障碍相关的疾病。
• PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20120165566A1

  公开（公告）日：2012-06-28

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，它们是蠕动素受体的拮抗剂，并且在治疗与该受体相关的疾病和蠕动功能障碍的方面是有用的。
• Processes for Intermediates for Macrocyclic Compounds
  申请人：Marsault Éric

  公开号：US20110245459A1

  公开（公告）日：2011-10-06

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及一种新型的大环化合物，其化学式为（I），以及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及化合物（I），其为胃动素受体拮抗剂，可用于治疗与该受体和/或运动功能障碍相关的疾病。
• US8129561B2
  申请人：——

  公开号：US8129561B2

  公开（公告）日：2012-03-06